NCT07169552View on ClinicalTrials.gov

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

September 30, 2027

Conditions

NSCLC

Interventions

DRUG

HC010

HC010 Q3W intravenous infusion

Trial Locations (1)

200123

Shanghai East Hospital, Shanghai

Sponsors

Lead Sponsor

HC Biopharma Inc.

All Listed Sponsors

lead

HC Biopharma Inc.

INDUSTRY

NCT07169552 - HC010 in First-line PD-L1 Positive Advanced NSCLC Patients | Biotech Hunter | Biotech Hunter